Jazz Pharmaceuticals plc (JAZZ) Discusses FDA Approval and Commercial Launch of ZIIHERA for First-Line HER2-Positive GEA August 25, 2026 4:30 PM EDT
Company Participants
John Bluth – Head of Investor Relations
Robert Iannone – Executive VP, Chief Medical Officer and Global Head of Research & Development
Chumi Khurana
Samantha Pearce – Executive VP & Chief Commercial Officer
Conference Call Participants
Jessica Fye – JPMorgan Chase & Co, Research Division
Marc Goodman – Leerink Partners LLC, Research Division
Gregory Renza – Truist Securities, Inc., Research Division
Annabel Samimy – Stifel, Nicolaus & Company, Incorporated, Research Division
Jason Gerberry – BofA Securities, Research Division
Leonid Timashev – RBC Capital Markets, Research Division
Alexandra von Riesemann – Piper Sandler & Co., Research Division
Gary Nachman – Canaccord Genuity Corp., Research Division
Sean Laaman – Morgan Stanley, Research Division
David Hoang – Deutsche Bank AG, Research Division
Joseph Thome – TD Cowen, Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Ziihera GEA Investor Webcast Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to turn the call over to your speaker for today, Rob — John Bluth, Head of Investor Relations. Please go ahead.
John Bluth
Head of Investor Relations
Thank you, operator, and thank you all for joining us. We’re excited to discuss the FDA approval in U.S. commercial launch of Ziihera in first-line HER2-positive metastatic gastroesophageal adenocarcinoma, or GEA.
The slide presentation accompanying this webcastis available on the Investors section of our website, and you can also reference the press release we issued regarding the FDA approval of Ziihera. Also on our website, you can find a link to the approved label.
On Slide 2, I’d like to remind you that today’s webcast includes forward-looking statements, such as those related to our future financial and operating results, growth potential and anticipated
